1. Worldwide analysis of actionable genomic alterations in lung cancer and targeted pharmacogenomic strategies
- Author
-
Gabriela Echeverría-Garcés, María José Ramos-Medina, Ariana González, Rodrigo Vargas, Alejandro Cabrera-Andrade, Isaac Armendáriz-Castillo, Jennyfer M. García-Cárdenas, David Ramírez-Sánchez, Adriana Altamirano-Colina, Paulina Echeverría-Espinoza, María Paula Freire, Belén Ocaña-Paredes, Sebastián Rivera-Orellana, Santiago Guerrero, Luis A. Quiñones, and Andrés López-Cortés
- Subjects
Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
Based on data from the Global Cancer Statistics 2022, lung cancer stands as the most lethal cancer worldwide, with age-adjusted incidence and mortality rates of 23.6 and 16.9 per 100,000 people, respectively. Despite significant strides in precision oncology driven by large-scale international research consortia, there remains a critical need to deepen our understanding of the genomic landscape across diverse racial and ethnic groups. To address this challenge, we performed comprehensive in silico analyses and data mining to identify pathogenic variants in genes that drive lung cancer. We subsequently calculated the allele frequencies and assessed the deleteriousness of these oncogenic variants among populations such as African, Amish, Ashkenazi Jewish, East and South Asian, Finnish and non-Finnish European, Latino, and Middle Eastern. Our analysis examined 117,707 variants within 86 lung cancer-associated genes across 75,109 human genomes, uncovering 8042 variants that are known or predicted to be pathogenic. We prioritized variants based on their allele frequencies and deleterious scores, and identified those with potential significance for response to anti-cancer therapies through in silico drug simulations, current clinical pharmacogenomic guidelines, and ongoing late-stage clinical trials targeting lung cancer-driving proteins. In conclusion, it is crucial to unite global efforts to create public health policies that emphasize prevention strategies and ensure access to clinical trials, pharmacogenomic testing, and cancer research for these groups in developed nations.
- Published
- 2024
- Full Text
- View/download PDF